Marshall Wace
CATX icon

Marshall Wace’s Perspective Therapeutics CATX Stock Holding History

Marshall Wace’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-406,732
Closed -$1.12M – 3229
2025
Q4 		$1.12M Buy
+406,732
New +$1.16M ﹤0.01% 1872
2025
Q3 		– Sell
-520,707
Closed -$1.79M – 2930
2025
Q2 		$1.79M Sell
520,707
-614,738
-54% -$1.62M ﹤0.01% 1610
2025
Q1 		$2.42M Buy
1,135,445
+328,273
+41% +$985K ﹤0.01% 1394
2024
Q4 		$2.57M Sell
807,172
-683,619
-46% -$5.58M ﹤0.01% 1337
2024
Q3 		$19.9M Buy
1,490,791
+206,849
+16% +$2.75M 0.02% 511
2024
Q2 		$12.8M Sell
1,283,942
-613,231
-32% -$8.87M 0.02% 630
2024
Q1 		$22.6M Buy
+1,897,173
New +$16.2M 0.03% 471
2021
Q4 		– Sell
-4,842
Closed -$31K – 3890
2021
Q3 		$31K Buy
+4,842
New +$33K ﹤0.01% 2949

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's CATX Position: Q1 2026 in Review

Marshall Wace sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 406,732 shares — an estimated $1.12M sold.

Marshall Wace first reported a position in CATX in Q3 2021 and held it in 8 quarters. The position peaked at $22.6M in Q1 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Marshall Wace reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 406,732 Perspective Therapeutics shares in Q1 2026, an estimated $1.12M.
  • Marshall Wace first reported a position in Perspective Therapeutics in Q3 2021 and held it in 8 quarters.
  • Marshall Wace's Perspective Therapeutics position peaked at $22.6M in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.